1Buhl R. Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review[J]. Respir Med, 2003, 97(2):123 - 129.
2Babu KS, Arshad SH, Holgate ST, et al. Omalizumab, a novel antiIgE therapy in allergic disorders[ J]. Expert Opin Biol Ther, 2001, 1(6): 1049 - 1058.
3Milgrom H. Is there a role for treatment of asthma with omalizumab[J]. Arch Dis Child, 2003, 88(1): 71 -74.
4Gennnaro DA. Therapy of allergic bronchial asthma with omalizumab:anti-IgE monoclonal antibody[J]. Expert Opin Biol Ther, 2003, 3(2): 371 -376.
5Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders[ J]. Am J Respir Crit Care Med, 2001, 164(8Pt2): S6 - 11.
6Marone G, Spadaro G, Palumbo C, et al. The anti-IgE/anti-FcεRIαautoantibody network in allergic and autoimmune diseases [ J ]. Clin Exp Allergy, 1999, 29:17-27.
7Sutton BJ, Gould HJ. The human IgE network[J]. Nature, 1993,366(6454): 421 -428.
8Michael PR, Adrian WZ, Andreas N, et al. Molecular Basis for Nonanaphylactogenicity of a Monoclonal anti-IgE Antibody [ J ]. J Immunol, 2000, 165:813-819.
9Kolbinger F, Saldanha J, Hardman N, et al. Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies[J]. Protein Eng, 1993, 6(8): 971 -980.
10Chang TW. The pharmacological basis of anti-IgE therapy[ J]. Nat Biotechnol, 2000, 18(2): 157 - 162.
